+44 20 8123 2220
info@marketpublishers.com

Europe Cancer Diagnostics Market by Product (IVD [Microarray, Immunoassay, PCR, Sequencing], Imaging [CT, MRI, Mammography, Ultrasound]) Cancer Type (Breast, Lung, Colon, Prostate), End User (Hospital, Imaging Center, Pharmaceutical) - Forecast to 2031

https://marketpublishers.com/r/EA4B2E4EABE3EN.html
Date: February 2024
Pages: 209
Price: US$ 4,175.00 (Single User License)
ID: EA4B2E4EABE3EN

Abstracts

Europe Cancer Diagnostics Market by Product (IVD [Microarray, Immunoassay, PCR, Sequencing], Imaging [CT, MRI, Mammography, Ultrasound]), Cancer Type (Breast, Lung, Colon, Prostate), End User (Hospital, Imaging Center, Pharmaceutical)—Global Forecast to 2031.

The Europe cancer diagnostics market is projected to reach $12.21 billion by 2031, at a CAGR of 5.6% from 2024 to 2031.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report analyzes key industry drivers, restraints, challenges, and opportunities. The growth of this market is driven by the rising prevalence of cancer, supporting initiatives for early cancer diagnosis, and increasing investments and funding for cancer research. Additionally, the supporting initiatives toward precision diagnostics for cancer are expected to generate growth opportunities for the players operating in the Europe cancer diagnostics market.

However, the high cost of imaging systems restrains the growth of this market. Additionally, the lack of skilled professionals and insufficiencies in the implementation of cancer screening programs pose a significant challenge to the market's growth.

Among the products, in 2024, the IVD segment is expected to account for the largest share of the Europe cancer diagnostics market. IVD instruments provide precise, reliable screening and diagnostic testing through simple workflows and integrated software. Furthermore, IVD consumables assist healthcare providers in obtaining vital information regarding genetic abnormalities, tumor markers, and other diagnostic indicators to monitor disease development, guide treatment decisions, and assess therapy responses in cancer patients. The large market share of this segment is attributed to the advancements in IVD technology, the commercial availability of a diverse range of IVD reagents & consumables for the diagnosis of cancer, and the recurring use of IVD consumables.

Among the cancer types, in 2024, the breast cancer segment is expected to account for the largest share of the Europe cancer diagnostics market. The increase in breast cancer cases, increasing healthcare expenditure, and inclusion of certain advanced technologies such as NGS in the reimbursement have propelled the demand for cancer diagnostics for breast cancer. Additionally, government initiatives promoting breast cancer awareness regarding diagnosis and treatment boost breast cancer diagnosis. For instance, in October 2023, Galderma SA (Switzerland) launched a new breast cancer campaign called ‘Facing Breast Cancer Together’, this campaign focuses on providing support and education about breast cancer awareness. Galderma has partnered with the National Breast Cancer Foundation (NBCF) to promote breast cancer awareness.

Among the end users, in 2024, the hospitals & diagnostic laboratories segment is expected to account for the largest share of the Europe cancer diagnostics market. The large market share of this segment is attributed to the increasing cancer cases, the higher purchasing power of hospitals and diagnostic laboratories, well-equipped operating & diagnostic rooms, the presence of highly skilled healthcare professionals, ease in accessibility, better health coverage for hospital-based healthcare services from various private & group insurance plans, and the increasing number of hospitals and expansion of diagnostic laboratories.

An in-depth analysis of the Europe cancer diagnostics market provides detailed qualitative and quantitative insights into major countries, namely Germany, France, U.K., Italy, Spain, Switzerland, Netherlands, and Rest of Europe. In 2023, Germany is estimated to account for the largest share of the Europe cancer diagnostics market. The market growth in Germany is attributed to the increasing prevalence of cancer, the high adoption of advanced technologies, the established healthcare systems, rising healthcare expenditures, increasing investments and funding for cancer research, and

initiatives to raise awareness about cancer diagnosis.

Some of the key players operating in the Europe Cancer Diagnostics market report are F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V. (Netherlands), Abbott Laboratories (U.S.), Illumina, Inc. (U.S.), Siemens Healthineers AG (Germany), GE HealthCare Technologies Inc. (U.S.), Koninklijke Philips N.V (Netherlands), FUJIFILM Holdings Corporation (Japan), Canon Medical Systems Corporation (a subsidiary of Canon Inc.) (Japan), and Hologic, Inc. (U.S.).

Scope of the Report:

Europe Cancer Diagnostics Market Size & Trend Analysis—by Product

In Vitro Diagnostics

- IVD Consumables
- Kits & Assays
- Reagents
- IVD Instruments
- Polymerase Chain Reaction (PCR) Systems
- Microarray Readers
- Immunoassay Analyzers
- Sequencers
- Other IVD Instruments
- IVD Software & Services

(Other IVD instruments include in-situ hybridization, hematology analyzers, and clinical chemistry analyzers)

Diagnostic Imaging

- Imaging Instruments
- Computed Tomography (CT)
- Magnetic Resonance Imaging (MRI)
- Mammography
- Ultrasound
- Other Imaging Instruments

(Other imaging instruments include Positron Emission Tomography (PET) and X-ray)

- Imaging Consumables
- Contrast Agents
- Syringes and Injectors
- Contrast Delivery Systems
- Skin Markers
- Phantoms
- Other Imaging Consumables

(Other imaging consumables include films, gels, transducers, and probes, among others)

- Imaging Software and Services

Europe Cancer Diagnostics Market Size & Trend Analysis—by Cancer Type

Breast Cancer

Lung Cancer

Colorectal Cancer

Prostate Cancer

Other Cancer Type

Note: Other cancer types include leukemia, lymphoma, stomach, ovarian, melanoma, kidney, and cervical cancers.

Europe Cancer Diagnostics Market Size & Trend Analysis—by End User

Hospital & Diagnostics Laboratories

Diagnostic Imaging Centers

Pharmaceutical & Biotechnology Companies

Academic & Research Institutes

Europe Cancer Diagnostics Market Size & Trend Analysis—by Country

Germany

France

Italy

U.K.

Spain

Switzerland

+44 20 8123 2220
info@marketpublishers.com

Netherlands

Rest of Europe

+44 20 8123 2220
info@marketpublishers.com

Contents

10. COMPANY PROFILES (BUSINESS OVERVIEW, FINANCIAL OVERVIEW, PRODUCT PORTFOLIO, AND STRATEGIC DEVELOPMENTS, SWOT ANALYSIS)

11. APPENDIX

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Europe Cancer Diagnostics Market by Product (IVD [Microarray, Immunoassay, PCR, Sequencing], Imaging [CT, MRI, Mammography, Ultrasound]) Cancer Type (Breast, Lung, Colon, Prostate), End User (Hospital, Imaging Center, Pharmaceutical) - Forecast to 2031

Product link: https://marketpublishers.com/r/EA4B2E4EABE3EN.html

Price: US$ 4,175.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/EA4B2E4EABE3EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below

+44 20 8123 2220
info@marketpublishers.com

and fax the completed form to +44 20 7900 3970